Leerink Partnrs Issues Negative Estimate for A Earnings

Agilent Technologies, Inc. (NYSE:A) – Stock analysts at Leerink Partnrs lowered their Q3 2026 earnings per share (EPS) estimates for Agilent Technologies in a research note issued to investors on Wednesday, August 27th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $1.52 for the quarter, down from their previous estimate of $1.53. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.58 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ Q4 2026 earnings at $1.65 EPS, FY2026 earnings at $5.91 EPS and FY2027 earnings at $6.48 EPS.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.37. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period last year, the firm earned $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS.

Other analysts have also recently issued reports about the company. Robert W. Baird increased their price objective on Agilent Technologies from $141.00 to $142.00 and gave the company an “outperform” rating in a research note on Thursday. Wells Fargo & Company increased their price objective on Agilent Technologies from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday. TD Cowen increased their price objective on Agilent Technologies to $150.00 and gave the company a “buy” rating in a research note on Thursday, May 29th. UBS Group dropped their target price on Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a report on Thursday, May 29th. Finally, Wall Street Zen raised Agilent Technologies from a “hold” rating to a “buy” rating in a report on Saturday, June 28th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $139.25.

Agilent Technologies Stock Up 0.5%

Shares of NYSE A opened at $125.63 on Monday. The stock has a market cap of $35.69 billion, a P/E ratio of 29.49, a PEG ratio of 3.91 and a beta of 1.24. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. Agilent Technologies has a 12-month low of $96.43 and a 12-month high of $153.84. The business’s fifty day simple moving average is $118.39 and its 200-day simple moving average is $116.36.

Hedge Funds Weigh In On Agilent Technologies

Several hedge funds have recently made changes to their positions in the company. Verdence Capital Advisors LLC grew its holdings in shares of Agilent Technologies by 5.0% during the second quarter. Verdence Capital Advisors LLC now owns 1,818 shares of the medical research company’s stock worth $215,000 after purchasing an additional 86 shares during the last quarter. M&T Bank Corp boosted its stake in shares of Agilent Technologies by 0.4% during the second quarter. M&T Bank Corp now owns 23,205 shares of the medical research company’s stock worth $2,738,000 after buying an additional 86 shares during the period. CENTRAL TRUST Co boosted its stake in shares of Agilent Technologies by 3.7% during the second quarter. CENTRAL TRUST Co now owns 2,522 shares of the medical research company’s stock worth $298,000 after buying an additional 89 shares during the period. Burney Co. boosted its stake in shares of Agilent Technologies by 4.8% during the second quarter. Burney Co. now owns 1,957 shares of the medical research company’s stock worth $231,000 after buying an additional 90 shares during the period. Finally, Valeo Financial Advisors LLC boosted its stake in shares of Agilent Technologies by 3.0% during the first quarter. Valeo Financial Advisors LLC now owns 3,449 shares of the medical research company’s stock worth $403,000 after buying an additional 102 shares during the period.

Insider Activity

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the firm’s stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the transaction, the chief executive officer owned 37,448 shares of the company’s stock, valued at approximately $4,397,893.12. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.